Trials / Completed
CompletedNCT00005027
Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Barbara Ann Karmanos Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer.
Detailed description
OBJECTIVES: * Determine the response rate of patients with advanced renal cell carcinoma when treated with rebeccamycin analogue. * Assess the quantitative and qualitative toxicities associated with this drug in this patient population. OUTLINE: Patients receive rebeccamycin analogue IV over 30-60 minutes daily for 5 days. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 23-44 patients will be accrued for this study within 9-18 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | becatecarin |
Timeline
- Start date
- 2000-06-01
- Primary completion
- 2005-03-01
- Completion
- 2005-03-01
- First posted
- 2003-08-08
- Last updated
- 2013-04-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00005027. Inclusion in this directory is not an endorsement.